retatrutide trial weight loss data Eli Lilly infiltrates anti-obesity market as Phase III for begins Retatrutide, a new weight loss

PMC 8216772

Specifically, there were lower rates of all-cause mortality and substantially fewer hospitalizations and emergency department visits. GLP-1 receptor agonists and dual GLP-1/GIP agonists have rapidly transformed the treatment landscape for Type 2 diabetes and obesity

These include reducing the risk of heart failure, stroke, and kidney disease, preserving beta-cell function, enhancing insulin sensitivity, maintaining cholesterol levels, and lowering the risk of thyroid tumours [6][7]

Yet intense exercise depletes glutamine stores faster than our bodies can replenish on their own

Hence, the potential benefits and risks must be thoroughly discussed with Dr